InnoCare Pharma Ltd. (33C)
Market Closed
11 Aug, 07:31
XDUS 
€
1. 65
+0.06
+3.7736%
€
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
0 Eps
€ 1.59
Previous Close Want to track 33C and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
33C closed today higher at €1.65, an increase of 3.7736% from yesterday's close, completing a monthly increase of 24.0602% or €0.32. Over the past 12 months, 33C stock gained 24.0602%.
33C is not paying dividends to its shareholders.
The last earnings report, released on Mar 26, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on HKEX (HKD).
33C Chart
InnoCare Pharma Ltd. (33C) FAQ
What is the stock price today?
The current price is €1.65.
On which exchange is it traded?
InnoCare Pharma Ltd. is listed on XDUS.
What is its stock symbol?
The ticker symbol is 33C.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has InnoCare Pharma Ltd. ever had a stock split?
No, there has never been a stock split.
InnoCare Pharma Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Jisong Cui Ph.D. CEO | XDUS Exchange | KYG4783B1032 ISIN |
| China Country | 1,176 Employees | - Last Dividend | - Last Split | - IPO Date |
InnoCare Pharma Ltd. is a leading biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for cancer and autoimmune diseases. Headquartered in Beijing, China, InnoCare Pharma plays a significant role in the healthcare sector by advancing innovative treatments that address unmet medical needs. The company's robust pipeline emphasizes targeted therapies and small molecule drugs, aiming to improve patient outcomes with effective and safe medical solutions. InnoCare Pharma's operations span research and development, clinical trials, and eventual product commercialization, impacting both domestic and international markets. A cornerstone of its strategy is leveraging strategic partnerships and cutting-edge technology to accelerate drug discovery processes and broaden its therapeutic portfolio. Through its commitment to high-quality innovation, InnoCare Pharma contributes significantly to the biotech industry, positioning itself as a vital player in addressing pressing global health challenges. Its extensive research initiatives and collaborations underscore its market significance, aimed at paving the way for breakthroughs in the treatment of serious diseases.
Contact Information
Address: Building 8
Phone: 86 10 6660 9999
Website: https://www.innocarepharma.com
